JP2014122214A5 - - Google Patents

Download PDF

Info

Publication number
JP2014122214A5
JP2014122214A5 JP2013241509A JP2013241509A JP2014122214A5 JP 2014122214 A5 JP2014122214 A5 JP 2014122214A5 JP 2013241509 A JP2013241509 A JP 2013241509A JP 2013241509 A JP2013241509 A JP 2013241509A JP 2014122214 A5 JP2014122214 A5 JP 2014122214A5
Authority
JP
Japan
Prior art keywords
neuregulin
sustained release
release composition
composition
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013241509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014122214A (ja
JP5948306B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014122214A publication Critical patent/JP2014122214A/ja
Publication of JP2014122214A5 publication Critical patent/JP2014122214A5/ja
Application granted granted Critical
Publication of JP5948306B2 publication Critical patent/JP5948306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013241509A 2005-12-30 2013-11-22 心機能改善のためのニューレグリンの徐放 Active JP5948306B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75512405P 2005-12-30 2005-12-30
US60/755,124 2005-12-30
US75862606P 2006-01-13 2006-01-13
US60/758,626 2006-01-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008547836A Division JP5738516B2 (ja) 2005-12-30 2006-12-29 心機能改善のためのニューレグリンの徐放

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015119950A Division JP2015199757A (ja) 2005-12-30 2015-06-15 心機能改善のためのニューレグリンの徐放

Publications (3)

Publication Number Publication Date
JP2014122214A JP2014122214A (ja) 2014-07-03
JP2014122214A5 true JP2014122214A5 (https=) 2014-08-14
JP5948306B2 JP5948306B2 (ja) 2016-07-06

Family

ID=38227911

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008547836A Active JP5738516B2 (ja) 2005-12-30 2006-12-29 心機能改善のためのニューレグリンの徐放
JP2013241509A Active JP5948306B2 (ja) 2005-12-30 2013-11-22 心機能改善のためのニューレグリンの徐放
JP2015119950A Pending JP2015199757A (ja) 2005-12-30 2015-06-15 心機能改善のためのニューレグリンの徐放

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008547836A Active JP5738516B2 (ja) 2005-12-30 2006-12-29 心機能改善のためのニューレグリンの徐放

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015119950A Pending JP2015199757A (ja) 2005-12-30 2015-06-15 心機能改善のためのニューレグリンの徐放

Country Status (9)

Country Link
US (3) US20070190127A1 (https=)
EP (3) EP2918283B1 (https=)
JP (3) JP5738516B2 (https=)
AU (1) AU2006332340B2 (https=)
BR (1) BRPI0620819A2 (https=)
CA (2) CA2634974A1 (https=)
ES (2) ES2530526T3 (https=)
RU (1) RU2457854C2 (https=)
WO (1) WO2007076701A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
BRPI0820538B1 (pt) * 2007-11-16 2021-08-17 Mind-Nrg Sa Usos de uma isoforma recombinante solúvel de neuregulina-1, e composição farmacêutica ou kit
CN102159236A (zh) * 2008-07-17 2011-08-17 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
JP2012509908A (ja) * 2008-11-28 2012-04-26 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
JP5743898B2 (ja) * 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
CN102245189B (zh) * 2008-12-03 2015-06-17 阿莫塞特公司 改善梗死区灌注的组合物以及血管损伤修复方法
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
EP3087998B1 (en) * 2009-06-09 2019-09-04 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin based methods for treating heart failure
WO2011006072A2 (en) * 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
WO2011011388A2 (en) * 2009-07-22 2011-01-27 Children's Medical Center Corporation Neuregulin induced regeneraton of heart muscle muscle
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. ニューレグリンに基づく心不全の治療方法
JP5709880B2 (ja) * 2009-10-23 2015-04-30 アモーサイト インコーポレイテッド 血管の機能不全による進行性心筋傷害治療のための組成物および方法
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US10894815B2 (en) 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN104758922A (zh) * 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CA3149964A1 (en) * 2019-09-03 2021-03-11 Michelle Wykes Methods and agents for determining patient status

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
FR2621486B1 (fr) 1987-10-07 1990-01-26 Synthelabo Utilisation de derives de pyrrolo(3,2,1-hi)indole pour obtenir un medicament destine au traitement du diabete
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US6406713B1 (en) * 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
JPH02226533A (ja) 1989-02-27 1990-09-10 Mitsubishi Electric Corp 情報記録媒体
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ATE163230T1 (de) 1993-03-09 1998-02-15 Epic Therapeutics Inc Makromolekulare mikropartikel und verfahren zu ihrer herstellung
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5554730A (en) 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FI943071L (fi) 1993-06-24 1994-12-25 Takeda Chemical Industries Ltd Anti-endoteliiniainetta pysyvästi vapauttava valmiste
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP3342873B2 (ja) * 1995-03-10 2002-11-11 ジェネンテク・インコーポレイテッド gas6による受容体活性化
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2257839C (en) * 1996-07-12 2012-10-23 Genentech, Inc. Gamma-heregulin
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6419961B1 (en) * 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
SK283760B6 (sk) 1996-10-15 2004-01-08 The Liposome Company, Inc. Farmaceutický prostriedok na dopravu bioaktívnych látok
ATE314054T1 (de) 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
US6593290B1 (en) * 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
WO1998035036A1 (en) * 1997-02-10 1998-08-13 Genentech, Inc. Heregulin variants
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
AU7727298A (en) 1997-06-06 1998-12-21 Regents Of The University Of Michigan, The Neuregulin response element and uses therefor
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
JP2001519400A (ja) * 1997-10-14 2001-10-23 ケンブリッジ ニューロサイエンス インク. ニューレグリン使用を含む治療法
CA2316273A1 (en) 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained-release composition, method of its production and use thereof
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6446242B1 (en) * 1999-04-02 2002-09-03 Actel Corporation Method and apparatus for storing a validation number in a field-programmable gate array
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
IL153052A0 (en) 2000-05-23 2003-06-24 Cenes Pharmaceuticals Inc Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2002000207A1 (en) 2000-06-27 2002-01-03 Mi Tech Company Limited The controlled release preparation of insulin and its method
DE60140625D1 (de) 2000-08-15 2010-01-07 Univ Illinois Verfahren zur herstellung von mikropartikeln
US6866866B1 (en) 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
IN190699B (https=) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US6890918B2 (en) * 2001-04-30 2005-05-10 Shire Laboratories, Inc. Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers
JP2004535401A (ja) * 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
US6838093B2 (en) 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
EP2400021B1 (en) 2002-03-26 2016-11-30 Zensun (Shanghai) Science & Technology, Co., Ltd. ErbB3 based methods and compositions for treating neoplasms
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
JP2012509908A (ja) 2008-11-28 2012-04-26 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
EP3087998B1 (en) 2009-06-09 2019-09-04 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin based methods for treating heart failure
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Similar Documents

Publication Publication Date Title
JP2014122214A5 (https=)
EP2528616B1 (en) Neuregulin based compositions and uses thereof for preventing or treating myocardial ischemia-reperfusion injury
ES2661500T3 (es) Variantes de HMGB1 y sus usos
PE20220283A1 (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento
Wang et al. Human Skeletal Muscle Nebulin Sequence Encodes a Blueprint for Thin Filament Architecture: SEQUENCE MOTIFS AND AFFINITY PROFILES OF TANDEM REPEATS AND TERMINAL SH3 (∗)
EP2200427B1 (en) Use of neuregulin for organ preservation
KR102007757B1 (ko) 심부전을 치료하기 위한 조성물 및 방법
RU2738158C2 (ru) Состав препарата нейрегулина
Jiao et al. Dermatopontin, a shell matrix protein gene from pearl oyster Pinctada martensii, participates in nacre formation
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
EA201590611A1 (ru) Новые молекулы, связывающие il-17a, и их медицинское применение
BRPI1010120A2 (pt) composição de surfactante reconstituído melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante ( sp-c)
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
Stephens et al. A functional analysis of Wnt inducible signalling pathway protein− 1 (WISP-1/CCN4)
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
Matsui et al. Transgelin-1 (SM22α) interacts with actin stress fibers and podosomes in smooth muscle cells without using its actin binding site
Aunis et al. Chromogranins: current concepts: structural and functional aspects
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
WO2014050908A1 (ja) ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物
AR071696A1 (es) Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos.
AU2017232582A1 (en) Method for producing activated hepatocyte growth factor (HGF)